{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"1.0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7"},{"groupId":"OG001","value":"25.3"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"57.6"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"3.0"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"12.1"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"description":"Safety of afatinib as indicated by intensity and incidence of worst adverse events graded according to National Cancer Institute (NCI) Common terminology criteria for adverse events (CTCAE) Version 3.0 (R04-0474).","groups":[{"description":"Subjects receiving starting doses 40 mg of Afatinib daily.","id":"OG000","title":"BIBW 40mg"},{"description":"Subjects receiving starting doses 50 mg of Afatinib daily.","id":"OG001","title":"BIBW 50mg"}],"paramType":"NUMBER","populationDescription":"Treated set","reportingStatus":"POSTED","timeFrame":"First administration of trial medication until 28 days after last administration of trial medication, up to 93 months.","title":"Safety of BIBW 2992 as Indicated by Intensity and Incidence of Worst Adverse Events Graded According to NCI CTCAE Version 3.0","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}